166 related articles for article (PubMed ID: 20299498)
41. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
42. Prostate cancer update: 2007.
Lin AM; Small EJ
Curr Opin Oncol; 2008 May; 20(3):294-9. PubMed ID: 18391629
[TBL] [Abstract][Full Text] [Related]
43. [CLINICAL SURVEILLANCE OF PROSTATE CANCER--COMPARISON WITH CLINICAL MASS STUDY IN JAPAN].
Takada T; Minato N; Koga M; Sugao H
Nihon Hinyokika Gakkai Zasshi; 2015 Apr; 106(2):79-88. PubMed ID: 26415357
[TBL] [Abstract][Full Text] [Related]
44. Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)--a comparison between 2004-2006 and 2007-2009.
Tanaka N; Hirayama A; Yoneda T; Yoshida K; Shimada K; Konishi N; Fujimoto K
BMC Cancer; 2013 Dec; 13():588. PubMed ID: 24325407
[TBL] [Abstract][Full Text] [Related]
45. Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA.
Fujimoto H; Nakanishi H; Miki T; Kubota Y; Takahashi S; Suzuki K; Kanayama HO; Mikami K; Homma Y
Int J Urol; 2011 Dec; 18(12):876-81. PubMed ID: 22142466
[TBL] [Abstract][Full Text] [Related]
46. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan.
Onozawa M; Hinotsu S; Tsukamoto T; Oya M; Ogawa O; Kitamura T; Suzuki K; Naito S; Namiki M; Nishimura K; Hirao Y; Akaza H
Jpn J Clin Oncol; 2014 Oct; 44(10):969-81. PubMed ID: 25098707
[TBL] [Abstract][Full Text] [Related]
47. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.
Akaza H; Hinotsu S; Cooperberg MR; Chung BH; Youl Lee J; Umbas R; Tsukamoto T; Namiki M; Carroll P
Jpn J Clin Oncol; 2013 Jul; 43(7):756-66. PubMed ID: 23723314
[TBL] [Abstract][Full Text] [Related]
48. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.
Cooperberg MR; Hinotsu S; Namiki M; Carroll PR; Akaza H
BJU Int; 2016 Jan; 117(1):102-9. PubMed ID: 25238114
[TBL] [Abstract][Full Text] [Related]
49. Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012.
Tanaka N; Nakai Y; Miyake M; Anai S; Inoue T; Fujii T; Konishi N; Fujimoto K
BMC Cancer; 2017 Sep; 17(1):616. PubMed ID: 28865421
[TBL] [Abstract][Full Text] [Related]
50. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor.
Koppie TM; Grossfeld GD; Miller D; Yu J; Stier D; Broering JM; Lubeck D; Henning JM; Flanders SC; Carroll PR
J Urol; 2000 Jul; 164(1):81-8. PubMed ID: 10840429
[TBL] [Abstract][Full Text] [Related]
51. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
Cooperberg MR; Hinotsu S; Namiki M; Ito K; Broering J; Carroll PR; Akaza H
J Clin Oncol; 2009 Sep; 27(26):4306-13. PubMed ID: 19667269
[TBL] [Abstract][Full Text] [Related]
52. Indications and practice with androgen deprivation therapy.
Moul JW; Kibel AS; Roach M; Dreicer R
Urology; 2011 Nov; 78(5 Suppl):S478-81. PubMed ID: 22054918
[TBL] [Abstract][Full Text] [Related]
53. Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
Lee W; Lim B; Kyung YS; Kim CS
Int J Urol; 2022 May; 29(5):414-420. PubMed ID: 35133691
[TBL] [Abstract][Full Text] [Related]
54. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cooperberg MR; Vickers AJ; Broering JM; Carroll PR
Cancer; 2010 Nov; 116(22):5226-34. PubMed ID: 20690197
[TBL] [Abstract][Full Text] [Related]
55. The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-Oncological Research Group registration.
Tanaka N; Fujimoto K; Hirayama A; Samma S; Momose H; Kaneko Y; Haramoto M; Hayashi Y; Nakagawa Y; Otani T; Watanabe S; Hirao Y
BMC Urol; 2011 Apr; 11():6. PubMed ID: 21524283
[TBL] [Abstract][Full Text] [Related]
56. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer.
Boevee SJ; Venderbos LD; Tammela TL; Nelen V; Ciatto S; Kwiatkowski M; Páez A; Malavaud B; Hugosson J; Roobol MJ
Eur J Cancer; 2010 Nov; 46(17):3082-9. PubMed ID: 21047590
[TBL] [Abstract][Full Text] [Related]
57. Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015.
Nakai Y; Tanaka N; Fujii T; Miyake M; Anai S; Hori S; Shimizu T; Onishi M; Ichikawa K; Onishi K; Fujimoto K
Int J Urol; 2021 Nov; 28(11):1164-1170. PubMed ID: 34355430
[TBL] [Abstract][Full Text] [Related]
58. Establishment of Korean prostate cancer database by the Korean Urological Oncology Society.
Ahn H; Kim HJ; Jeon SS; Kwak C; Sung GT; Kwon TG; Park JY; Paick SH
Investig Clin Urol; 2017 Nov; 58(6):434-439. PubMed ID: 29124243
[TBL] [Abstract][Full Text] [Related]
59. Effective treatment for early-stage prostate cancer--possible, necessary, or both?
Smith MR
N Engl J Med; 2011 May; 364(18):1770-2. PubMed ID: 21542749
[No Abstract] [Full Text] [Related]
60. [Novelties in diagnostics and treatment of prostate cancer].
Riesz P; Nyírádi P
Orv Hetil; 2016 Mar; 157(11):410-4. PubMed ID: 26947089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
